创新视角下我国医药制造业集聚水平分析--基于DO指数的企业精准地理位置测度  

Research on Agglomeration Level of China Pharmaceutical Industry under the Perspective of Innovation:A Precise Geographic Measurement of Enterprise Locations Based on the Duranton and Overmen Index

作　　者：谢静[1] 马爱霞[1] 

机构地区：[1]中国药科大学国际医药商学院,江苏南京211198

出　　处：《科技管理研究》2017年第15期170-178,共9页Science and Technology Management Research

摘　　要：为更好地分析我国医药制造行业的集聚现状及创新水平,首先通过建立行业集聚、创新集聚、创新共聚三者间的理论框架,厘清三者间可能存在的逻辑关系;以我国医药制造企业的精准地理位置为基准数据,采用DO指数进行行业集聚、创新集聚及创新共聚水平测度。对比理论框架发现:除化学药品原药制造子行业发展较为成熟,其他子行业发展水平还有待提高,特别是中药饮片加工业和生物、生化制品制造业的整体创新水平还比较低下。To analyze the innovation and agglomeration level of Chinese pharmaceutical manufacturing industry, fi^tly, this paper establishes a theoretical framework of industrial agglomeration, innovation agglomeration and innovation copolymerization, and clarifies the possible logical relations between the three factors; then, based on the precise location of pharmaceutical manufacturing enterprises in China, the DO indexes proposed by Duranton and Overman are applied to measure the level of industry agglomeration, innovation agglomeration and innovation copolymerization. Comparing the theoretical framework, we reach several conclusions： chemical medicine manufacturing industry is relatively mature, but the other studied industries require further development, among which the Chinese herbal medicine industry and biological, biochemical products manufacturing industry are with the lowest innovation level.

关 键 词：医药制造子行业 行业集聚 创新集聚 创新共聚 DO指数 

分 类 号：F426.72[经济管理—产业经济]